Cystadenocarcinoma, Serous

"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)

Descriptor ID	D018284
MeSH Number(s)	C04.557.470.200.025.480.240 C04.557.470.590.480.240
Concept/Terms	Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinomas, Serous Serous Cystadenocarcinoma Serous Cystadenocarcinomas

Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Adenocarcinoma [C04.557.470.200.025]
Cystadenocarcinoma [C04.557.470.200.025.480]
Cystadenocarcinoma, Serous [C04.557.470.200.025.480.240]
Neoplasms, Cystic, Mucinous, and Serous [C04.557.470.590]
Cystadenocarcinoma [C04.557.470.590.480]
Cystadenocarcinoma, Serous [C04.557.470.590.480.240]

Below are MeSH descriptors whose meaning is related to "Cystadenocarcinoma, Serous".

Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.

Bar chart showing 10 publications over 7 distinct years, with a maximum of 3 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	1	0	1
2009	1	1	2
2010	2	1	3
2020	1	0	1
2021	1	0	1
2024	1	0	1
2025	1	0	1

Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.

Alvero AB, Wu S, Farrell A, Kim S, Wallbillich JJ, Winer I, Morris R, Spetzler D, Anderson ML, Puccini A, Jones NL, Herzog TJ, Thaker PH, Mor G, Gogoi RP. Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis. Gynecol Oncol. 2025 03; 194:71-79.

View in: PubMed
Pitiyarachchi O, Ansell PJ, Coleman RL, Dinh MH, Holman L, Leath CA, Werner T, DiSilvestro P, Morgan M, Tew W, Lee C, Cunningham M, Newton M, Edraki B, Lim P, Barlin J, Spirtos NM, Tewari KS, Edelson M, Reid T, Carlson J, Friedlander M. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70?years and over. Gynecol Oncol. 2024 08; 187:221-226.

View in: PubMed
Bronder D, Tighe A, Wangsa D, Zong D, Meyer TJ, Wardenaar R, Minshall P, Hirsch D, Heselmeyer-Haddad K, Nelson L, Spierings D, McGrail JC, Cam M, Nussenzweig A, Foijer F, Ried T, Taylor SS. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells. Dis Model Mech. 2021 11 01; 14(11).

View in: PubMed
Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, F?rkkil? A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968.

View in: PubMed
Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct; 20(7):1137-41.

View in: PubMed
Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. 2010 Aug; 9(8):2411-22.

View in: PubMed
Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, Odunsi K, Cheney RT. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol. 2010 Jun; 133(6):899-908.

View in: PubMed
Tchabo NE, McCloskey S, Mashtare TL, Andrews C, Singh AK, Mhawech-Fauceglia P, Odunsi K, Lele S, Jaggernauth W. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006. Gynecol Oncol. 2009 Nov; 115(2):249-56.

View in: PubMed
Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J. 2009 Mar-Apr; 15(2):176-81.

View in: PubMed
Galanis C, Zamani A, Cameron JL, Campbell KA, Lillemoe KD, Caparrelli D, Chang D, Hruban RH, Yeo CJ. Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. J Gastrointest Surg. 2007 Jul; 11(7):820-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement